Every 8-K that CARING BRANDS INC (CBRA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CBRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBRA filings page.
Caring Brands Inc. entered into an expanded multi-territory licensing agreement with SanPellegrino Cosmetics Private Limited for its Photocil and Hair Enzyme Booster products. The revised agreement, effective May 21, 2026, introduces a five-year initial term with automatic annual renewal.
The deal broadens SCPL’s licensed territory beyond India to include multiple LATAM countries, Russia, Australia and New Zealand, leveraging existing sublicense partnerships with Eris Lifesciences and Glenmark Pharmaceuticals. Caring Brands highlights that this expansion supports its strategy to grow revenue from patented, clinically validated skin and hair-growth products across high-growth international markets.
Caring Brands, Inc. filed a current report to correct an administrative error in its proxy materials. The company’s Definitive Proxy Statement for its annual meeting had incorrectly listed May 12, 2026 as the record date. The correct record date for determining stockholders entitled to receive notice of, and vote at, the annual meeting is May 14, 2026.
All other information in the original proxy statement remains unchanged, and only stockholders of record as of May 14, 2026 will be eligible to participate in the meeting. The company plans to file a revised definitive proxy statement reflecting this corrected date.
Caring Brands, Inc. received a Nasdaq Staff Delisting Determination after falling out of compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity. The company’s latest Form 10-K reported stockholders’ equity of $2,091,324, triggering the notice.
Caring Brands has 45 days, until May 22, 2026, to submit a plan to regain compliance and could receive up to 180 days, until October 4, 2026, to demonstrate compliance if Nasdaq accepts the plan. The notice does not immediately affect trading, and the stock continues to trade on Nasdaq under the symbol CABR, but failure to regain compliance could lead to delisting.
Caring Brands, Inc. entered into a $3.6 million private investment in public equity, issuing 3,789.74 shares of Series A Convertible Preferred Stock at $950 per share with a stated value of $1,000 and an 8% dividend. The preferred stock is convertible into common shares at $0.40 and is paired with 9,473,685 common warrants, also exercisable at $0.40 for five years, all subject to beneficial ownership limits and a 19.99% cap without shareholder approval.
The company plans to use $3.075 million of the proceeds to repurchase 6,250,000 common shares from insiders, reducing common shares outstanding from 14,761,925 to 8,511,925, with the balance for general corporate and working capital needs. The investor also obtained an option to invest up to an additional $4.0 million on similar terms and received a 12‑month right of first refusal on future financings, while the company agreed to register the resale of the underlying shares.
Caring Brands, Inc. reported that it has been issued two new United States patents. These patents cover proprietary methods and compositions that enhance enzymatic activity in hair follicles. Management explains that this intellectual property further strengthens protection around its Hair Enzyme Booster product and related technologies, potentially reinforcing its competitive position in hair-focused treatments.
Caring Brands, Inc. completed an initial public offering of 1,000,000 shares of common stock at $4.00 per share, raising approximately $4.00 million in gross proceeds and about $3.23 million in net proceeds. The deal was a firm commitment underwriting with D. Boral Capital LLC and includes a 45-day over-allotment option for up to 150,000 additional shares at the offering price, less the underwriting discount.
As part of the transaction, the underwriter received a warrant to purchase up to 30,000 shares of common stock at an exercise price of $4.00 per share, exercisable for five years starting 180 days after the closing, with up to about 4,500 additional warrant shares if the over-allotment is exercised. Company officers, directors, and 10% holders agreed to a 180-day lock-up on sales of common stock and related securities. The common stock was approved for listing on Nasdaq under the symbol CABR and began trading on November 13, 2025.